Histotripsy for Renal Cell Carcinoma (HRCC)
Histotripsy for Renal Cell Carcinoma: a Pilot Study for a Novel Focused Therapy With an Unmet Need
The project will be a pilot study in localised or metastatic renal cell carcinoma, assessing safety, local control, and exploratory immune endpoints. Outcomes from this work will inform rational combinations with targeted agents and immune checkpoint blockade and may define a new, image-guided, non-invasive modality for renal cell carcinoma. If successful, histotripsy could become a new non-thermal, local therapy for renal cell carcinoma with dual benefits of debulking and immune activation achieving strong clinical and scientific impact.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
Study Design and Methodology
This study will enrol 15 patients with localised or metastatic renal cell carcinoma. Patients will be identified from clinic, and undergo a comprehensive evaluation, including imaging studies and laboratory tests, to confirm the diagnosis and assess their eligibility for histotripsy.
Procedure
Histotripsy will be performed by dedicated team of oncologist, urologist and radiologist who have undergone accredited training on Histotripsy aiming to achieve the best clinical outcomes and ensure patient safety. Patients are typically placed under general anaesthesia (GA) or monitored anaesthesia care (MAC) with real-time monitoring. The component of the Histotripsy machine that generates sound waves is positioned within a soft, flexible membrane filled with specially treated water, which rests on the patient's abdomen and facilitates the transmission of sound waves to the targeted tissue. The procedure will be delivered in a single session or multiple sessions by ultrasound, depending on the size and location of tumours.
Assessment
Patients will be invited to complete a questionnaire for pain score assessment before and after histotripsy.
Blood samples will be collected for clinical evaluation and laboratory tests at baseline, followed by 1-day, 30-day, 60-day, and 90-day after histotripsy, aligned with existing feasibility and trial schedules. Blood tests and cellular analysis such as complete blood profile, liver and renal function tests, tumour markers, immune markers and biomarkers etc. will be performed each time. Patients will be asked for consent for 15ml blood collection for the cellular analysis.
Serial post-histotripsy imaging (CT/MRI) will also be arranged. Imaging within 36-hour after histotripsy will be proceeded to confirm the ablation zone and assess complications. Post-procedure imaging at 1-, 3-, and 6-month will help to capture the sustainability of treatment effect, then per standard of care thereafter.
Admission and follow-up
Similar to other minimal invasive treatments, patients will be admitted one day prior, or on the day of procedure. After the procedure of histotripsy, patients may experience some discomfort in the treated area, but patients can often return to normal activities quickly. They could be discharged in few hours, or the next day after procedure depending on clinical conditions.
After discharge, follow-up consultations and assessments such as regular imaging and blood tests will be arranged accordingly.
Potential risk and discomfort
Blood drawn for laboratory tests can cause bruising at or near the site where the needle enters the vein and thus increase the risk of infection. Risks related to imaging scans will be explained prior to the procedures by the related doctors or medical professionals.
Procedure risk related to Histotripsy includes skin erythema or superficial burn injury, infection, bleeding, renal dysfunction, and abdominal wall injury or burn. Adverse post treatment event includes bleeding, infection, damage to surrounding structures etc. The medical team will monitor closely and response promptly.
Short-term effects
- Mild pain or soreness that usually responds to oral pain medication
- Low-grade fever and flu-like symptoms that typically resolve within 48 hours
- Temporary skin redness at the treatment site
- Mild abdominal discomfort
- Temporary changes in renal function tests
- Possible nausea or fatigue
- Transient haematuria
Potential serious complications
- Temporary decrease in kidney function
- Potential damage to surrounding organs (liver, lung, bowel, or stomach)
- Severe pain
- Need for extended hospital stay or additional treatment for serious complications
- Skin ulcer / necrosis requiring interventions
- Vascular thrombosis / dissection
Long-term complications
• Currently, there is no known long-term side effects from Histotripsy treatment. Ongoing research aims to evaluate the long-term outcomes.
In the event of complications arising from the study treatment, patients will be treated accordingly or referred for standard treatment and care.
Statistical analysis
Analysis will be performed for the 15 participants recruited, with basic demography (age, sex, medical history etc.), clinical evaluation, laboratory tests, imaging, treatment outcome with associated complication.
DATA AND BIOLOGICAL SAMPLES HANDLING
Patients will be invited to register on the Histotripsy (HistoSonics○R) Registry in Gleneagles Hospital Hong Kong for data collection. Collected personal and study data will be anonymised and stored in a password protected, encrypted database with the principal investigator and delegated staff in the long run. The principal investigator will be responsible for the safekeeping. Only investigators and delegated staff can have right to gain access to the data. All collected data and biological samples will be stored permanently for future review in histotripsy related research. Unused biological samples will be destroyed and discarded upon request, however, the results will remain a part of the overall research data if part of the sample has been proceeded.
Consent
Written voluntary consents will be obtained after full explanation of the study to patients before agreement of the histotripsy procedure.
Conflicts of interests
All investigators and funding bodies have no financial interests in the study.
Research ethics
The study will be performed in accordance with ethical principles that have their origin in the Declaration of Helsinki and are consistent with ICH/Good Clinical Practice, and applicable regulatory requirements Patient data protection.
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Professor Matthew Kin-liang CHIU, PhD
- Número de teléfono: +852 22554352
- Correo electrónico: mklc2@hku.hk
Ubicaciones de estudio
-
-
-
Hong Kong, Hong Kong
- Reclutamiento
- Gleneagles Hospital Hong Kong
-
Contacto:
- Professor Matthew Kin-liang CHIU, PhD
- Número de teléfono: +852 22554352
- Correo electrónico: mklc2@hku.hk
-
Sub-Investigador:
- Wing Hang Vince Lau, MBBS, FHKCR, FHKAM
-
Sub-Investigador:
- Chi-Yan Albert Chan, MBBS, MS, FRCSEd, FCSHK, FHKAM
-
Sub-Investigador:
- Justin Christopher Ng, MBBChBAO, LMCHK, MMED, FRCR
-
Sub-Investigador:
- Pei Wayne Lam, MBBS, LMCHK, FRCSed, FCSHK
-
Sub-Investigador:
- Cho Wing Bryan Li, MBBS, MRCP, FHKCP, FHKAM
-
Sub-Investigador:
- Shung Lai John Leung, MBBS, FRCSEd, FCSHK, FHKAM
-
Sub-Investigador:
- Lok Hei Clarence Leung, MBChB, FRCSEd, FCSHK, FHKAM
-
Sub-Investigador:
- Hin Kay John Ngan, MBBS, FHKCS, FHKAM, FRCSE
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Age ≥ 18 years old
- Fit for general anaesthesia
- Histologically confirmed renal cell carcinoma; radiological diagnosis acceptable if biopsy is not feasible
- With or without distant metastases
- Eastern Cooperative Oncology Group Performance Status (ECOG PS) grade 0-2
- Tumour visible and targetable by ultrasound with acceptable acoustic windows
- Adequate hematologic, hepatic, and renal function (eGFR ≥45mL/min, ≤14 days prior to the planned index procedure date).
Exclusion Criteria:
- Refusal to take part in clinical trial
- Not fit for general anaesthesia
- Poor general condition with limited life expectancy
- Uncontrolled coagulopathy
- The treatment of the tumour will not allow for an adequate margin as determined by the investigator
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Patients receiving Histotripsy procedure for renal cell cancer using the HistoSonics® Edison System
|
Patients with be admitted to Gleneages Hospital for histotripsy procedure. Pre-produce anaestetic assessment will occur and patients will be treated under general anasestetic with jet ventilation. Patient will be positioned in the left or right lateral position and a water tank will be placed over the patient's loin area. The histotripsy ultrasound and treatment head will be placed inside the water tank and image-guided histotripsy ablation of the kidney tumor will be performed. The expected length of hospital stay is 1 day after operation. Patient will undergo follow up with regular imaging up to 6 months. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
To assess efficacy
Periodo de tiempo: 90 days post procedure
|
Successful treatment percentage at 90 days on MRI/CT post-procedure |
90 days post procedure
|
|
To assess treatment safety
Periodo de tiempo: At 30 days
|
Freedom from index procedure related major complications, defined by Clavien-Dindo Classification Grade 3 or higher |
At 30 days
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Pain score assessment before and after histotripsy
Periodo de tiempo: At baseline (after inpatient admission and before histotripsy) and day 2 (before discharge of patient) on a 11-point scale Numeric Pain Rating Scale (NPRS).
|
At baseline (after inpatient admission and before histotripsy) and day 2 (before discharge of patient) on a 11-point scale Numeric Pain Rating Scale (NPRS).
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Neoplasias urogenitales
- Neoplasias por sitio
- Neoplasias
- Enfermedades urogenitales masculinas
- Enfermedades Renales
- Enfermedades urológicas
- Enfermedades urogenitales femeninas
- Enfermedades urogenitales femeninas y complicaciones del embarazo
- Neoplasias por tipo histológico
- Neoplasias Glandulares y Epiteliales
- Adenocarcinoma
- Neoplasias Urológicas
- Carcinoma
- Neoplasias Renales
- Carcinoma De Célula Renal
Otros números de identificación del estudio
Otros números de identificación del estudio
- GHK-2026-005
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .